USD10
UPB Shares
About Upstream BioUpstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
USD10
UPB Shares
About Upstream BioUpstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Stats
TRADING WINDOW
Open
CLOSES AT
8:00 PM GMT+0
MARKET CAP
$443.12M
OPEN PRICE
$8.38
LOW (1Y)
$5.14
HIGH (1Y)
$33.68
LOW (24H)
$8.16
HIGH (24H)
$8.60
VOLUME (24H)
$510.85K
35.99%
Price history
Time | Price | Change |
|---|---|---|
Today | $8.38 | |
1 Day | $8.45 | |
1 Week | $9.23 | |
1 Month | $8.09 |